Equine herpesvirus 1 (EHV-1) is an economically important disease in the horse community. It is highly contagious and spreads through direct horse-to-horse contact or indirect contact e.g. contaminated hands, equipment.1,3 Infection manifests into three different syndromes: abortion and early fetal death, respiratory disease, and neurologic disease.1,3 It is a common and burdensome DNA virus in horse populations globally. Moreover, the neurologic form of the disease is particularly troublesome due to associated degrees of paralysis and is seen in approximately 10% of infected horses. Current diagnostic testing requires use of PCR for specific diagnosis as clinical signs of EHV-1 mimic that of equine infl uenza, EHV-4 and other respiratory pathogens.2 EHV-1 imposes further risk due to potentially neuropathic disease thus providing the necessity for species discrimination during diagnosis.2 The Fluxergy EHV-1 assay provides reliable detection of the herpes subtype in deep nasopharyngeal swabs identifying EHV-1 in symptomatic horses or those that have been previously exposed to the virus.3 Further testing is required to confirm whether infection is neuropathic.